The findings suggest higher-intensity interventions are needed to maintain smoke-free homes and support smoking cessation in permanent supportive housing.
Searching for Solutions
Cannabis use screening, cannabis use disorder treatment, and additional intervention to prevent worsening severity are needed to minimize cannabis-related harms among older US adults.
No summary available
This toolkit includes four tools and templates designed to help states and community partners assess existing relationships, identify opportunities for increased coordination, and strengthen cross-sector collaborations across aging, disability, health, and housing systems.
In this sample, ADHD was associated with increased risk for SUDs and earlier onset of substance use.
Exposure to alcohol-related user-generated content on social media and engagement with self-generated content appear to be associated with alcohol use among young people, with largely consistent findings observed across studies.
Cannabis use was associated with a greater odds of signs of sleep-disordered breathing.
Cannabis is used for symptom relief by patients with cyclic vomiting syndrome (CVS). Chronic heavy cannabis use is associated with cannabinoid hyperemesis syndrome (CHS), a condition characterized by recurrent severe nausea, vomiting, and abdominal pain, and considered a subset of CVS.
Among adolescents in Northern California, USA, trends in incident cannabis use disorder rates appeared to increase following recreational cannabis legalization passage, with increasing rates persisting through retail implementation and three years post-passage.
Findings suggest an important population-level benefit of MOUD that may vary according to the prevalence of OUD and the medication type.
Rapid XR-BUP induction without SL-BUP stabilization was safe and associated with significant OD rate reductions in a shelter-based harm reduction setting.
These findings suggest that reported increases in ASD occurrence estimates from service-based surveillance may be influenced by detection-related factors.
Tavapadon (Juvmo, AbbVie) is the first and only selective D1/D5 dopamine receptor agonist for adults with Parkinson’s disease, marking the first new dopaminergic treatment approach for the PD in decades. Approval was based on the Phase 3 TEMPO clinical trial program, which demonstrated significant improvements in motor symptoms, daily functioning, and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease.
The AAPP membership has elected three members to serve on the 2027-2029 Board of Directors. Assuming their positions effective July 1, 2027, will be Drs. Michael McGuire, Sarah Thomason and Kara Wong.
No summary available
No summary available
No summary available
On Sept. 8, the DOL's Employee Benefits Security Administration (EBSA) published new interim guidelines for enforcing treatment limitations under the original 2008 Mental Health Parity and Addiction Equity Act. The Trump administration has signaled intent to create a new proposed rule entirely, but this interim guideline aims to clarify enforcement of the nonquantitative treatment limitation (NQTL) requirements in the meantime.
On Thursday, September 17, 2026, the Joint Commission of Pharmacy Practitioners (JCPP) convened leaders of national pharmacy organizations in Alexandria, Virginia, to explore healthcare megatrends shaping the future of pharmacy practice. AAPP was represented by AAPP President Suzie Harris and Executive Director Brenda Schimenti.
PCSS-MOUD added a supplemental course to its SUD 101 Core Curriculum: Managing Common Psychiatric Conditions in Patients with Substance Use Disorders, presented by Ellen L. Edens, MD. Check out this on-demand educational activity!
Psychedelic therapy and the current and future roles for psychiatric pharmacists in the USA
US drug overdose deaths involving stimulants without opioids continued to rise in 2024
Care Navigation for Methamphetamine Use Disorder-A Randomized Clinical Trial
Impact of Addiction Consult Service on Alcohol Use Disorder Medications and Postdischarge Outcomes
This is your chance to get involved with the important work being done by AAPP committees and editorial boards. Through October 28, AAPP will be accepting applications for volunteer openings anticipated for the 2027-2028 committee year which starts March/April. Selections will be made and announced no later than January 2027. Apply today!